AC Immune SA

Acimmune SA is a Swiss biotechnology firm that specializes in the development of therapeutics aimed at preventing and treating neurodegenerative diseases. The company is at the forefront of combating conditions such as Alzheimer's and Parkinson's disease through its innovative pipeline of proprietary technology platforms. These platforms focus on targeting misfolded proteins that play a crucial role in the pathology of neurodegenerative disorders. Acimmune collaborates with major pharmaceutical companies to bolster its research and enhance the effectiveness of its therapeutic solutions. Headquartered in Lausanne, Switzerland, the company is pivotal in the biopharmaceutical sector, particularly in advancing treatments for diseases that currently have limited or no cure. By focusing on precision medicine, Acimmune contributes significantly to the field of neuroscience and has a strong potential impact on improving long-term health outcomes for aging populations worldwide.